文献速递泌尿生殖腹部MR

前列腺癌MRI表型与基因组分类器的相关性:初步发现

Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.
PubMed 文献 · Eur Radiol · 2019-03-07

这项单中心回顾性研究纳入72例前列腺癌患者,将根治术标本中MRI定位病灶显微切割后用Decipher基因组分类器分析,发现MRI可见病灶(PI-RADS v2≥3)的Decipher评分高于MRI不可见病灶(≤2),PI-RADS v2与Decipher中度相关(r=0.54),在外周带病灶中区分Decipher低危与中高危的AUC为0.863。

要点

  • MRI可见前列腺癌病灶的Decipher评分高于MRI不可见病灶,平均差0.22(95%CI 0.13,0.32;p<0.0001)。
  • PI-RADS v2与Decipher评分中度相关(r=0.54),外周带病灶中AUC 0.863,高于前列腺癌分级分组AUC 0.780。
  • 多数(82.6%)MRI不可见病灶Decipher为低危,但仍有部分中高危病灶在MRI上不可见。

核心结论

  • 前列腺癌MRI表型与Decipher风险分组正相关,PI-RADS v2可较准确区分Decipher低危与中高危病灶,但部分Decipher中高危病灶在MRI上不可见。

研究设计与样本

  • 单中心回顾性研究,纳入72例非连续前列腺癌患者,2014年4月至2017年8月根治术前接受MRI,MRI定位病灶从根治标本显微切割后用Decipher分析,共89个病灶(23个MRI不可见[PI-RADS v2≤2],66个MRI可见[PI-RADS v2≥3]),采用线性回归评估预测因素,用相关系数r量化关联,用AUC评估PI-RADS v2区分Decipher低危(<0.45)与中高危(≥0.45)的准确性。

关键影像表现/征象

  • MRI可见病灶(PI-RADS v2≥3)的Decipher评分高于MRI不可见病灶(PI-RADS v2≤2),平均差0.22(95%CI 0.13,0.32;p<0.0001)。
  • 82.6%的MRI不可见病灶Decipher为低危(评分<0.45)。

诊断标准与关键数值

  • Decipher低危定义为评分<0.45,中高危定义为评分≥0.45。
  • PI-RADS v2与Decipher评分中度相关(r=0.54)。
  • 外周带病灶中PI-RADS v2区分Decipher低危与中高危的AUC为0.863,前列腺癌分级分组AUC为0.780,差值95%CI 0.01,0.15(p=0.018)。

临床应用与阅片要点

  • MRI表型(PI-RADS v2评分)与Decipher风险分组正相关,阅片时可结合基因组分类器信息评估病灶生物学潜能。
  • 部分Decipher中高危病灶在MRI上不可见,MRI阴性不能排除中高危基因组风险。
  • 原文指出MRI可与基因组检测联合用于识别可能具有早期转移生物学潜能的病灶。

局限性

  • 原文为初步发现(preliminary findings),结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We sought to evaluate the correlation between MRI phenotypes of prostate cancer as defined by PI-RADS v2 and the Decipher Genomic Classifier (used to estimate the risk of early metastases).

METHODS: This single-center, retrospective study included 72 nonconsecutive men with prostate cancer who underwent MRI before radical prostatectomy performed between April 2014 and August 2017 and whose MRI registered lesions were microdissected from radical prostatectomy specimens and then profiled using Decipher (89 lesions; 23 MRI invisible [PI-RADS v2 scores ≤ 2] and 66 MRI visible [PI-RADS v2 scores ≥ 3]). Linear regression analysis was used to assess clinicopathologic and MRI predictors of Decipher results; correlation coefficients (r) were used to quantify these associations. AUC was used to determine whether PI-RADS v2 could accurately distinguish between low-risk (Decipher score < 0.45) and intermediate-/high-risk (Decipher score ≥ 0.45) lesions.

RESULTS: MRI-visible lesions had higher Decipher scores than MRI-invisible lesions (mean difference 0.22; 95% CI 0.13, 0.32; p < 0.0001); most MRI-invisible lesions (82.6%) were low risk. PI-RADS v2 had moderate correlation with Decipher (r = 0.54) and had higher accuracy (AUC 0.863) than prostate cancer grade groups (AUC 0.780) in peripheral zone lesions (95% CI for difference 0.01, 0.15; p = 0.018).

CONCLUSIONS: MRI phenotypes of prostate cancer are positively correlated with Decipher risk groups. Although PI-RADS v2 can accurately distinguish between lesions classified by Decipher as low or intermediate/high risk, some lesions classified as intermediate/high risk by Decipher are invisible on MRI.

KEY POINTS: • MRI phenotypes of prostate cancer as defined by PI-RADS v2 positively correlated with a genomic classifier that estimates the risk of early metastases. • Most but not all MRI-invisible lesions had a low risk for early metastases according to the genomic classifier. • MRI could be used in conjunction with genomic assays to identify lesions that may carry biological potential for early metastases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Purysko AS, Magi-Galluzzi C, Mian OY, et al. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. Eur Radiol. 2019. PMID: 30847589. doi:10.1007/s00330-019-06114-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。